Ushbu ish iqtibos qilgan ishlar

52 ta ish

Ish: Genetic engineering in oncology based on CRISPR-Cas9 technology

1. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

   Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

   Maqola20174 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.020478

2. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

   Wanghong Hu, Zhenguo Zi, Yanling Jin +5

   Maqola20183 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.020506

3. Delivering CRISPR: a review of the challenges and approaches

   Christopher A. Lino, Jason C. Harper, James P. Carney +1

   Sharh maqola20183 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.051686

4. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

   Zhenguang Wang, Na Li, Kaichao Feng +14

   Maqola20213 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.102893

5. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

   Na Tang, Chen Cheng, Xingying Zhang +6

   Maqola20203 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296864

6. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

   Bryan D. Choi, Xiaoling Yu, Ana P. Castaño +14

   Maqola20192 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.020532

7. Nobel Prize 2020 in Chemistry honors CRISPR: a tool for rewriting the code of life

   Lukas Westermann, Björn Neubauer, Michael Köttgen

   Tahririyat maqolasi20202 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.051744

8. The Potential Revolution of Cancer Treatment with CRISPR Technology

   Dimitrios Stefanoudakis, Nikhita Kathuria‐Prakash, Alexander W. Sun +10

   Sharh maqola20232 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.082292

9. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing

   Muhammad Naeem, Saman Majeed, Mubasher Zahir Hoque +1

   Sharh maqola20202 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.452270

10. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

    Dana Stenger, Tanja A. Stief, Theresa Kaeuferle +12

    Maqola20202 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.475820

11. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735602

12. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735603

13. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735604

14. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735605

15. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735606

16. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735607

17. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735608

18. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735609

19. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735610

20. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735611

21. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735612

22. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735613

23. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735614

24. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735615

25. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.735616